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Alterations in maternal physiological adaptation during pregnancy lead to complications,
including abnormal birthweight and gestational diabetes. Maternal adaptations are driven by
placental hormones, although the full identity of these is lacking. This study unbiasedly
characterized the secretory output of mouse placental endocrine cells and examined whether
these data could identify placental hormones important for determining pregnancy outcome
in humans. Secretome and cell peptidome analyses were performed on cultured primary
trophoblast and fluorescence-activated sorted endocrine trophoblasts from mice and a pla-
cental secretome map was generated. Proteins secreted from the placenta were detectable in
the circulation of mice and showed a higher relative abundance in pregnancy. Bioinformatic
analyses showed that placental secretome proteins are involved in metabolic, immune and
growth modulation, are largely expressed by human placenta and several are dysregulated in
pregnancy complications. Moreover, proof-of-concept studies found that secreted placental
proteins (sFLT1/MIF and ANGPT2/MIF ratios) were increased in women prior to diagnosis of
gestational diabetes. Thus, placental secretome analysis could lead to the identification of
new placental biomarkers of pregnancy complications.
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The placenta forms the functional interface between themother and fetus that is essential for fetal development andgrowth during pregnancy. It is responsible for secreting a
plethora of endocrine meditators that induce local and systemic
changes in the mother to enable fetal nutrient and oxygen transfer
and prevent immunological rejection of the fetus1. Aberrant
placental function can lead to insufficient or inappropriate
adaptations in maternal physiology, with consequences for
pregnancy outcome and with immediate and lifelong impacts on
the health of both the mother and child. Indeed, placental mal-
function is a leading cause for the development of pregnancy
complications, such as preeclampsia (PE), gestational diabetes
mellitus (GDM), and intrauterine growth restriction (IUGR).
Combined, these complications affect up to 6–8% of pregnancies
in the UK (https://www.gov.uk/government/statistics/birth-
characteristics-england-and-wales-2014). Typically, these com-
plications are diagnosed in the second or even the third trimester
of gestation, after the complication has already manifested.
Moreover, current diagnosis methods, namely blood pressure and
proteinuria evaluation for PE, oral glucose tolerance test (OGTT)
for GDM, and uterine fundal height and ultrasound measures for
IUGR are performed at a specific time/s in gestation and the
development of the complication may not be detected in some
cases. Therefore, the identification of novel placental biomarkers
for earlier detection and improved diagnosis of pregnancy com-
plications is highly desirable. Moreover, the illumination of pla-
cental biomarkers may aid in the design of novel therapeutic
targets for pregnancy complications.
The notion that placental biomarkers may provide diagnostic
or prognostic value for pregnancy complications is a long-
standing and supported concept. For instance, detection of the
placental hormone, chorionic gonadotropin is used to confirm
pregnancy, reduced levels of pregnancy-associated plasma
protein-A in the maternal circulation are predictive of IUGR and
PE2 and an imbalance in placental derived angiogenic regulators,
like soluble fms-like tyrosine kinase 1 (sFLT1) and placental
growth factor (PIGF) can be predictive of PE3. However, studies
in experimental animals have demonstrated that the production
of many other protein hormones by the placenta could also be
important in determining pregnancy outcome1,4. In rodents,
placental lactogens/prolactins (PL/PRL), growth hormone (GH),
and insulin-like growth factor 2 (IGF2) modulate maternal
insulin and glucose levels during pregnancy and perturbed
expression of these proteins by the placenta have been associated
with GDM and abnormal fetal growth in humans. The placenta
also produces a wide variety of cytokines throughout pregnancy,
which contribute to the low-grade systemic inflammation and
induction of maternal insulin resistance that normally occurs in
the second half of pregnancy and some data suggest that placental
cytokine production is aberrant in women with poor pregnancy
outcomes like PE, GDM, and IUGR5. Additionally, the placenta
secretes inhibins, activins, and relaxins, which aid in the adap-
tation of the endocrine, renal, circulatory, and immune systems of
the mother during gestation1. Finally, the placenta secretes pro-
teases, inhibitors of peptidases, binding proteins and soluble
forms of receptors for steroids, growth factors, cytokines, and
circulating factors, like lipoproteins, which contribute to the
pleiotropic endocrine regulation of maternal physiology during
gestation and show some predictive value for conditions like
IUGR6–8. Thus, there is likely a constellation of protein mediators
secreted by the placenta that facilitate maternal adaptations and
ensure adequate fetal growth, required for a healthy pregnancy
outcome.
Transcriptomic analyses have informed on the repertoire of
hormones expressed by the human placenta in healthy and
complicated pregnancies9–12. However, these studies are
conducted mainly on samples obtained at delivery and involve
analysis of pieces of placenta tissue, which is heterogeneous in
nature and includes trophoblast, vascular, stromal, and specia-
lized immune cell types. Moreover, as powerful a tool it may be,
transcriptomic analyses on their own may not be sufficient to
identify the protein hormones secreted by the placenta. This is
because genes can be subjected to posttranscriptional and post-
translational regulatory mechanisms, such as alternative splicing,
folding, transport, localization, degradation, and secretion. Thus,
analysis of the secretome, the complete list of proteins secreted by
the placenta, would be invaluable for identifying placental bio-
markers of maternal and fetal wellbeing that could be altered
prior to the manifestation of a pregnancy complication.
The mouse is a valuable species for defining the placental
secretome. This is because hormone secretion by the placenta is
principally performed by trophoblast endocrine cells that are
conveniently arranged into a structure, termed the junctional
zone. The junctional zone is also discrete from, and forms under
distinct genetic instruction to, the labyrinthine zone, which per-
forms substrate transport function in the mouse placenta. This is
in contrast to humans, where the endocrine and transport func-
tions of the placenta are carried out by the same region/cell type,
the syncytiotrophoblast (STB), preventing the specific, sole
examination of placental hormone production. The mouse also
offers the key advantage that tools to selectively modify and
isolate endocrine cells in the placenta are now available13.
Moreover, despite some variations between mice and humans,
many mouse-specific hormone genes are structurally similar to
those in the human and perform similar functions (e.g., PRL/PL
and GH genes)1. Furthermore, many gene and protein networks
regulating placental development and function overlap in the two
species14,15.
Herein, we first established a method for obtaining primary
cultures of mouse placental endocrine cells from which the cells
and secretory output could be collected. As a complementary
approach, we also employed fluorescence-activated cell sorting
(FACS) to isolate endocrine cells from the placenta of mice. We
used mass spectrometry to unbiasedly identify the proteins in our
different mouse placental endocrine cell preparations and applied
a bioinformatic pipeline to refine a placental secretome map. We
then overlaid our placental secretome map to a compilation of
RNA/protein expression databases publicly available for the
human placenta in women with pregnancy complications,
including PE, GDM, and IUGR to identify secreted placental
proteins that could be clinically important. As a proof of concept,
we quantified the abundance of four secreted placental protein
candidates (sFLT1, MIF, ANGPT2, and IGF2) and their ratios to
one another in blood samples taken from women who had
uneventful/healthy pregnancy outcomes and those who devel-
oped GDM (both populations were normotensive). We found
that sFLT1 was altered in abundance in women with GDM and
moreover, the ratios of sFLT1 or ANGPT2 to MIF were altered in
the first trimester of pregnancy in women who went on to
develop and be diagnosed with GDM in the second trimester of
pregnancy. Finally, we identified several transcription factors
(TFs) that are predicted to be important for controlling endocrine
function of the placenta and determining pregnancy outcome.
Our methodology and placental secretome map may be useful in
identifying additional placental biomarkers for pregnancy
complications.
Results
We first wanted to establish a method for obtaining primary
cultures of mouse placental endocrine cells from which secretory
output could be collected and unbiasedly characterized. We
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harvested placentas at day 16 of gestation from wild-type females
mated with males expressing Cre-EGFP under the Tpbpa pro-
moter, which is specifically active in the trophoblast endocrine
cells of the junctional zone13 (Fig. 1a). Day 16 of gestation was
chosen as this corresponds to when all the endocrine cells in the
mouse placenta have differentiated and are non-proliferating.
Moreover, this is when the junctional zone is largest in absolute
terms. The Tpbpa-Cre-EGFP reporter was used to visualize the
trophoblast endocrine cells, which were found to be enriched in
the second layer of our Percoll gradient (between 1.028 and 1.050
g/ml; Fig. 1a, b). Trophoblast cells from this layer were then
cultured for up to 120 h and the optimal time point for secretome
analysis was identified to be 48 h based on dynamics of tropho-
blast density (Krt18 expression) and the levels of viability (XTT
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02214-x ARTICLE
COMMUNICATIONS BIOLOGY |           (2021) 4:701 | https://doi.org/10.1038/s42003-021-02214-x | www.nature.com/commsbio 3
levels), necrosis (LDH levels), and apoptosis markers (p53 and
Bax expression) throughout the culturing (Fig. 1c). As expected,
the 48 h primary cultures contained a high density of endocrine
trophoblasts, as indicated by the high expression of Tpbpa and
comparatively very low expression of the transport labyrinth zone
marker,Mct4 (Fig. 1d). These cultures contained all three types of
junctional zone cells, i.e., the endocrine spongiotrophoblasts,
glycogen cells, and giant cells, as evidenced by the expression of
their unique gene markers Prl8a8, Gjb3, and Hand1, respectively
(Fig. 1e, f).
Peptidome and secretome analysis of primary cultured tro-
phoblast cells from mouse placenta. We then determined the
secretome of our primary mouse trophoblast endocrine cell cul-
tures. This involved performing LC-MS/MS on both the cells and
conditioned medium from the cultures at 48 h and then applying
a bioinformatics pipeline (Fig. 1g). We identified a total of 1534
and 1445 proteins in the cells and conditioned medium of the
cultures, respectively. After considering only proteins that were
detected in four out of five samples, protein lists were then
converted to their corresponding gene ID and expression by the
mouse placenta verified using publicly available RNA datasets
(Supplementary Table 1). As we wanted to ultimately translate
our findings from the mouse to humans, we additionally overlaid
our converted mouse gene lists with publicly available RNA
datasets for the human placenta (Supplementary Table 1) and
performed systematic orthologue searches. To further refine our
lists to secreted proteins, we applied SignalP and gene ontology
(GO) analysis to capture proteins that employ both the “con-
ventional”, as well as “unconventional” secretion pathways (see
“Methods” for details). This resulted in a refined list of 158 and
257 secreted proteins detected in the cultured cells and condi-
tioned medium (110 were common between the sample types),
respectively, that are expressed by both the mouse and human
placenta. Reactome pathway analysis revealed that the proposed
functions of secreted proteins in the cultured cells and condi-
tioned medium were largely similar, with the highest scoring
pathways including those involved in the immune system, neu-
trophil degranulation, homeostasis, and IGF regulation (Fig. 1h, i).
All data outputs at each step of the pipeline, including the pro-
teins/genes expressed in the mouse but not the human placenta
can be found in GitHub (https://github.com/CTR-BFX/2020-
Napso_Sferruzzi-Perri).
Peptidome and secretome analysis of sorted endocrine cells
from the mouse placenta. As a complementary approach to the
primary trophoblast cultures, endocrine cells from the mouse
placenta on day 16 of pregnancy were isolated using FACS. This
was performed by mating the Tpbpa-Cre-EGFP mouse line to the
double-fluorescent Cre reporter line, mTmG16 (Fig. 2a). As
expected, placentas obtained from these matings showed EGFP in
the junctional zone of the placenta, whereas the labyrinth,
decidua, and fetus were positive for tdTom (Fig. 2b, c). Moreover,
sorting the EGFP-positive cells provided us with highly enriched
isolates of junctional zone cells (as indicated by the high
expression of Tpbpa, with little to low detection of the Mct4 gene;
Fig. 2d) containing the three major endocrine cell types of the
mouse placenta (Fig. 2e). Using LC-MS/MS we identified a total
of 1142 proteins in the sorted placental endocrine cells (Fig. 2f).
Applying a similar pipeline to the analysis of cultured placental
endocrine cells, we narrowed down our list of proteins obtained
in the sorted placental endocrine cells to 105 secreted proteins
that are shared between the mouse and human placenta (Fig. 2f).
GO analysis indicated that these secreted placental proteins
function in pathways related to the immune system, neutrophil
degranulation, and metabolism of proteins, among others
(Fig. 2g). All data outputs at each step of the pipeline, including
the proteins/genes expressed in the mouse but not the human
placenta can be found in GitHub (https://github.com/CTR-BFX/
2020-Napso_Sferruzzi-Perri). Proteins detected in the sorted
placental endocrine cells that were not predicted to be secreted
were analyzed by GO analysis. This revealed that many proteins
detected are proposed to play roles in protein synthesis, transla-
tion, and metabolism, amongst others and are in line with their
possible regulatory role in modulating the function of placental
endocrine cells (Supplementary Fig. 1 and Supplementary
Data 1).
Creating a placental secretome map. Given that the LC-MS/MS
method is unbiased but cannot exhaustively characterize the
entire proteome of a given set of samples, we then combined the
lists of secreted placental proteins expressed by mouse and
human placenta obtained using the two methods presented
above, to generate a more comprehensive placental secretome
map (Fig. 3a). This approach resulted in a total of 319 secreted
proteins that are expressed by both mouse and human placenta
(Fig. 3b) and another 31 that are specific to the mouse (Supple-
mentary Fig. 2). We aligned our list of 319 secreted placental
proteins with data from single-cell RNA-Seq analysis of the
human placenta at 8 and 24 weeks of gestation17 and found that
94% of our proteins (299 out of 319) were expressed in the STB
(Fig. 3b, e). We also aligned our list of 319 secreted placental
proteins with data on the conditioned media from trophoblast
Fig. 1 Detection of secreted proteins in primary cultures of mouse trophoblast. a Workflow for the detection of secreted proteins in primary cultures of
trophoblast from mice at day 16 of pregnancy. b Visualization of EGFP (Tpbpa-Cre-EGFP reporter; green) by fluorescence microscopy to identify the Percoll
gradient layer containing trophoblast endocrine cells. Cells in layers were counterstained with Hoechst dye (blue) and photographed at magnification ×10
(scale bar 3 mm). c Primary cell culture viability (determined by XTT; blue line), cell death (LDH release levels; red line), trophoblast density (Krt18 gene
expression; black line), and apoptosis (p53 and Bax gene expression; purple and orange lines, respectively) from time 0 to 120 h. d Proportion of junctional
zone (Tpbpa gene expression; dark pink bar) and labyrinthine zone (Mct4 gene expression; light blue bar) trophoblast at 0 and 48 h. e Relative abundance
of the three junctional zone endocrine cell types, spongiotrophoblast, glycogen cells, and giant cells (gene expression of Prl8a8, Gjb3, and Hand1,
respectively and indicated by purple, green, and light blue bars, respectively) at 0 and 48 h of culture. f Representative images of cells stained in situ using
RNAscope probes against; Tpbpa, Prl8a8, Gjb3, and Hand1 to visualize trophoblast endocrine cells, spongiotrophoblast (SpT), glycogen cells (Gly), and giant
cells (TGC), respectively. g Pipeline and results of the analysis of proteins detected by mass spectrometry in cultured trophoblast and their conditioned
medium including conversion to RNA sequences and overlay with published RNA data for the mouse and human placenta. Secreted proteins identified
using SignalP and combined gene ontology (GO) terms: extracellular region, extracellular exosome, extracellular region parts, and signal IP. h, i Pathway
over-representation analysis using Reactome pathway by STRING V.11 for the 158 and 257 secreted placental proteins in cultured trophoblast and their
conditioned medium, respectively that are expressed by both mouse and human placenta. XTT, LDH, and gene expression data relative to geometric mean
of three housekeeping genes: Gapdh, RPII, and Hprt are presented as mean ± SEM and expressed relative to expression at time 0 h. Asterisks denote
statistical significance versus time 0 h, using two-way ANOVA (b) or t-test (c, d), **p < 0.01, ****p < 0.001, n= 6–10 of four pooled litters.
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organoids prepared from first trimester human placenta18 and
identified 56 secreted placental proteins in common (Fig. 3b).
Notably, 24 proteins of our 319 placental secretome list have been
previously identified as potential damage-associated molecular
pattern (DAMP) proteins19. However, we also found evidence
that at least 19 of these are also detectable in mouse plasma, either
by us or in previous studies20,21 (Supplementary Table 2). GO
analysis of the complete list of 319 proteins/genes demonstrated
that they play roles in the response to stimuli and stress and
regulation of organismal process (Supplementary Data 2).
Moreover, many placental proteins identified are implicated in
protein and signaling receptor binding and contain protein-
interacting domains, such as serpin, conserved sites, and the EGF-
like domains, observations which are overall consistent with the
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notion that they are secreted (Supplementary Data 2). Using gene
expression enrichment analysis for mouse and human tissues, we
found that 20 of the proteins were highly expressed (>10 fold) in
the mouse placenta compared to other tissues (Fig. 3c) and four
secreted placental proteins, TFPI2, SERPINE2, IGF2, and FLT1
were enriched in the human placenta compared to other tissues
(Fig. 3d). Further alignment of our complete list of secreted
placental proteins with single-cell RNA-Seq analysis17 of the
human placenta revealed that several proteins were enriched
predominantly in the STB, including FLT1, TFPI2, and ANGPT2
(Fig. 3e). Moreover, all the proteins that we identified are
reported to be expressed by the STB, extravillous cytotrophoblast
(EVT), or cytotrophoblast of the human placenta. In a screen of
mouse plasma, we found that 45 of the proteins in our placental
secretome map were detectable, of which 24 showed a higher
relative abundance in pregnancy (between 1.5-fold and 52-fold
increase compared to non-pregnant state; Fig. 3f and Supple-
mentary Data 3). A further seven secreted proteins exclusively
expressed by the mouse placenta were identified and highly
enriched in the plasma of mice during pregnancy, as expected
(Supplementary Fig. 3 and Supplementary Data 4).
Placental secretome map is enriched in proteins that are dif-
ferentially expressed in human pregnancy complications. We
wanted to know whether our placental secretome map could help
us to identify placental proteins that may serve as circulating
biomarkers/diagnostic indicators of maternal and fetal wellbeing
in human pregnancy. We collated publicly available RNA and
protein expression datasets for the human placenta from preg-
nancies complicated by PE, GDM, IUGR, small for gestational
age (SGA), and large of gestational age (LGA) (Supplementary
Table 3). We then overlaid our placental secretome map to our
collated database of placental RNA/protein expression for these
pregnancy complications. This identified 119 secreted proteins
that were dysregulated in the human placenta in the pregnancy
complications studies (Fig. 4a). There was some overlap in the
expression of secreted placental proteins between pregnancy
complications and, aside from LGA, all complications showed an
altered expression of ANGPT2, FLT1, IGF2, and TIMP2 (Fig. 4a).
Of note, FLT1 and IGF2 are particularly enriched in the human
placenta compared to other tissues (see also Fig. 3f). Furthermore,
we found several secreted placental proteins that were uniquely
altered in specific pregnancy complications. For instance, we
found 18 secreted placental proteins that were only altered in the
placenta of women with GDM, 47 specifically altered in PE and 5
uniquely altered in IUGR pregnancies (Fig. 4a). Of those uniquely
altered in PE and IUGR, secreted placental proteins TFPI2 and
SERPINE2, respectively, are reported to be highly enriched in the
human placenta compared to other tissues. GO analysis revealed
that secreted placental proteins uniquely altered in GDM are
involved in the metabolism of proteins and extracellular matrix
organization (Supplementary Data 5), those altered in PE largely
function in the immune system and platelets (Supplementary
Data 6) and those changed in IUGR are implicated in fibril,
collagen, and laminin formation (Supplementary Data 7).
MIF/sFLT1 and ANGPT2/MIF ratios are altered in human
GDM blood samples. We wanted to know whether our secre-
tome map may be useful in identifying placental biomarkers that
could be measured in the circulation of women and aid in the
detection of a pregnancy complication. To test this possibility, we
analyzed the abundance of secreted placental proteins in blood
taken from women at booking (12 weeks of gestation) and after
glucose tolerance testing (28 weeks of gestation) who were sub-
sequently classified as normoglycemic or diagnosed with GDM.
Maternal clinical characteristics and pregnancy outcomes for the
women with normal glucose tolerance or GDM are shown in
Table 1. We quantified the abundance of the following secreted
placental proteins, sFLT1, ANGPT2, MIF, and IGF2 as they were
highly enriched in human placenta and/or differentially altered in
several pregnancy complications (Fig. 4a). We first visualized the
cell-specific expression of these proteins at the maternal–fetal
interface in early human pregnancy using the CellxGene tool
(https://maternal-fetal-interface.cellgeni.sanger.ac.uk/)22. FLT1
was shown to be highly and mainly expressed in STB and EVTs
(Fig. 4b), whilst ANGPT2, MIF, and IGF2 were more broadly
expressed by trophoblast cell populations (Supplementary Fig. 4).
All four secreted placental proteins were detectable in the
maternal circulation as early as 12 weeks of gestation (Fig. 4c and
Supplementary Fig. 5). Furthermore, several showed changes in
abundance with gestational age and in those women, who
developed GDM. ANGPT2 and MIF declined in the maternal
circulation between 12 and 28 weeks of gestation, in line with the
reduction in placental expression indicating that the placenta is
the main source (Fig. 3f). However, the decline in MIF with
gestational age was not observed in women who developed GDM
(due, in part to non-significantly lower values in GDM versus
healthy women at 12 weeks). Moreover, sFLT1 circulating levels
were overall, significantly elevated in the circulation of women
with GDM diagnosis (p= 0.05). In contrast, IGF2 levels in the
maternal circulation were not significantly different between 12
and 28 weeks of gestation or in women who developed GDM
(Fig. 4c and Supplementary Fig. 5). As pregnancy complications
can be caused by an alteration of several pathways and biological
systems, it is common to evaluate the relationship between the
abundance of different biomarkers. We found that the ratio of
sFLT1 to MIF concentration was increased by 210% (p= 0.0003)
and ANGPT2 to MIF was increased by 97% (p= 0.02) in women
at 12 weeks of gestation who went on to develop GDM compared
to the healthy pregnancies (Fig. 4d).
A transcriptional network controlling placental proteome
highlights links with pregnancy complications. We wanted to
gain further information on the regulation of placental endocrine
function and its significance for determining pregnancy outcome.
Fig. 2 Detection of secreted proteins in sorted mouse trophoblast endocrine cells. a Workflow for the cell sorting and protein expression analysis of
mouse trophoblast endocrine cells from mice at day 16 of pregnancy. b Fluorescent image of placenta showing EGFP in Tpbpa positive cells (junctional zone
of the placenta; green) and tdTom (red) for Tpbpa negative cells. The fetus for the placenta is also shown, and as expected is only tdTom positive. Scale bar
is 250mm. c Representative image of cell sorting of EGFP/tdTom cells by fluorescence-activated cell sorting. d Expression of junctional zone and labyrinth
zone markers, Tpbpa (dark pink bar) andMct4 (light blue bar), respectively in the EGFP and TdTom sorted cells. e Expression of markers for junctional zone
cell types, spongiotrophoblast cell (Prl8a8; purple bar), glycogen cells (Gjb3; green bar), and giant cells (Hand1: light blue bar). f Pipeline and results of the
analysis of proteins detected by mass spectrometry in sorted Tpbpa+/EGFP cells. g Pathway over-representation analysis using Reactome pathway by
STRING V.11 for the 105 secreted placental proteins expressed by both mouse and human placenta. Data presented as mean ± SEM and genes expressed
relative to geometric mean of two housekeeping genes: RPII and Hprt. Asterisks denote statistical significance to the Tpbpa+/EGFP sorted cells, using t-
test, *p < 0.05, **p < 0.01, n= 5 for each group.
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To this aim, we searched for TFs that had significant enrichment of
binding sites at the promoters of genes encoding the 319 proteins in
our placental secretome map (Fig. 3a). We used two computational
tools, Analysis of Motif Enrichment and Ingenuity Pathway Ana-
lysis (IPA) and identified 33 common TFs expressed by trophoblast
cells in human placenta and controlling the expression of a total of
96 proteins from our placental secretome map (Supplementary
Data 8). All of these TFs were expressed by the STB at 8 weeks of
gestation, when their placental secreted targets were too. Further-
more, the expression of ten of these TFs has been reported to be
perturbed in human pregnancy complications (Fig. 5a). These ten
TFs control the expression of 36 members of the placental pro-
teome map, 20 of which are reported to be differentially expressed
in human pregnancy complications (Fig. 5b). Of note was ARNT2,
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which is reported to be dysregulated in PE and IUGR and impli-
cated in the control of ten genes encoding proteins in the placental
secretome, of which five were further reported to be altered in
pregnancy complications (Supplementary Data 8). PLAG1 and
CREB1 were specifically altered in the placenta from women with
GDM and proposed to be key in regulating of placental secreted
proteins like IGF2 and FLT1, which were also identified as altered
in expression in such pregnancies. FOS, MYCN, and NFYC were
found to be altered in PE pregnancies and are predicted to mod-
ulate the gene expression of up to 11 proteins in our secretome list
that are also reported to be differentially expressed in PE (Fig. 5a
and Supplementary Data 8).
Discussion
Our study has established a comprehensive secretome map of the
placenta. By utilizing transgenic mouse lines for tracking pla-
cental endocrine cells, together with advanced molecular techni-
ques and bioinformatics analysis, we have characterized a
placental secretome map relevant for both mouse and human
pregnancy. To achieve this, we performed mass spectrometry on
three types of samples: (1) primary cultures containing mouse
placental endocrine cells, (2) conditioned media from primary
cultures of mouse placental endocrine cells, and (3) endocrine
cells isolated from the mouse placenta by FACS. A robust
bioinformatics pipeline was then used to integrate our proteins
lists and to include in our analysis only proteins expressed by
both the mouse and human placenta, as well as those destined to
be secreted. By overlaying our secretome map to publicly avail-
able datasets for the human placenta, we were able to identify that
several secreted placental proteins were altered in pregnancy
complications including GDM, PE, and IUGR. Moreover, in
proof-of-concept experiments using blood samples from women
who were healthy or developed GDM, our findings suggest that
the relative abundance of secreted placental candidates identified
using our secretome map, may be altered as early as week 12 of
gestation, which predates traditional clinical diagnosis at
24–28 weeks. Lastly, we identified TFs that are likely to govern the
expression of placental hormones with important implications for
pregnancy outcome. Taken together, our data demonstrate that
our methodology and placental secretome map may illuminate
promising biomarker candidates as early diagnostic indicators
and therapeutic targets for pregnancy complications linked to
placental malfunction. Moreover, our methodology and findings
may have relevance for understanding the significance of pla-
cental endocrine function in mammalian development and
pregnancy physiology, more broadly.
Three parallel approaches were used to obtain lists of secreted
placental proteins that could be integrated as a secretome map.
This was fundamentally important, as we wanted to maximize
our ability to detect secreted placental proteins without being
limited by sample preparation, method sensitivity and specificity.
We adapted published methods23 and used the Tpbpa-Cre-EGFP
mouse line13 to obtain primary cell cultures containing a high
density of mouse placental endocrine cells. By monitoring the
behavior of our cultured cells, we were able to show that at 48 h of
culture, cell viability was stable, with no increase in cell necrosis
or cell death. Furthermore, at 48 h, our primary cell cultures
contained the three main endocrine cell types of the mature
mouse placenta. We analyzed the cultured cells and conditioned
media separately, as proteins can be secreted at low concentra-
tions into the culture media, resulting in recovery difficulties.
Moreover, salts and other compounds in the media may interfere
with protein detection. Furthermore, highly abundant proteins
can mask the detection of lowly expressed proteins, resulting in
selective detection or a misrepresentation of the proteome when
analyzing cultured cells. To further increase the sensitivity of
detecting secreted placental proteins, we concentrated the con-
ditioned media of our primary cell cultures prior to mass spec-
trometry and likely due to this, we obtained a larger list of
secreted placental proteins from the conditioned media (26 pro-
teins in the mouse and 257 in mouse and human) compared to
the cultured cells (5 proteins in mouse and 158 in mouse and
human). However, our primary placental endocrine cell cultures
were not pure, and cells may alter their protein expression when
cultured. As a complementary approach, we also identified the
proteins in freshly isolated mouse placental endocrine cells using
the Tpbpa-Cre-EGFP and mTmG murine lines and FACS. This
approach delivered highly pure samples containing all three
placental endocrine lineages. However, some trophoblast giant
cells in the mouse placenta may have been lost due to size lim-
itation of the nozzle for the FACS (100 µm). Moreover, both the
preparation of primary cultures and fluorescence-activated sort-
ing of mouse placental endocrine cells resulted in a relatively
lower abundance of glycogen cells than expected for the mouse
placenta at day 16 (normally the relative proportion of endocrine
cell types is spongiotrophoblast > glycogen cells > trophoblast
giant cells). This is somewhat expected, as glycogen cells are
sensitive to lysis and may thus be particularly sensitive to the
sample preparation technique. Nevertheless, 112 secreted pla-
cental proteins (7 proteins in mouse and 105 in mouse and
human) were detected in the pure placental endocrine cell iso-
lates, of which 82% were also found in cultured cells. Reactome
pathway analysis of individual protein lists revealed that the
proposed functions of secreted proteins in the cultured cells,
conditioned culture media, and placental endocrine cell isolates
were overall similar, with the highest scoring pathways including
those related to the immune system, homeostasis, and IGF reg-
ulation. However, several of the proteins detected were specific to
one approach/sample type, which reinforces our approach of
combining different sample types/methodologies to optimize and
broaden the detection of proteins secreted by the placenta.
Indeed, the combination of the three methodologies enabled the
creation of map of 319 secreted proteins expressed by both mouse
and human placenta and another 31 specific to the mouse.
Fig. 3 Secretome map of the placenta. a Integrating the lists of secreted placental proteins expressed by mouse and human placenta and obtained using
our different methods to generate a comprehensive placental secretome map. Proteins expressed by mouse but not human placenta shown in
Supplementary Fig. 2. b Venn diagram showing the overlay of placental secretome map (pink circle) with first trimester trophoblast organoid secretome
(Turco18; orange circle) and single-cell RNA-seq analysis for human placenta at 8 weeks of gestation (Liu17; green circle). Proteins in the placental
secretome map that are highly enriched in the placenta of mouse (c) and human (d) compared to other tissues using TissueEnrich and indicated by the
darkest of blue color. e Cell-specific expression of the top 30 most highly expressed genes in the placental secretome map using single-cell RNA-seq data
for the human placenta (see “Results” text for details). Data represent results after adjusting p values based on Bonferroni correction with highest log1
expression indicated by yellow and lowest log1 expression indicated by dark blue. f Heat map generated using Heatmapper showing the relative abundance
of peptides secreted by the placenta (MS peak areas normalized to the bovine insulin internal standard), which are detected in non-pregnant (n= 3) and
pregnant mouse plasma (on day 16 of pregnancy, n= 8) with highest row Z-score indicated by yellow and lowest row Z-score indicated by dark blue. CTB
cytotrophoblasts, EVT extravillous trophoblasts, NP non-pregnant, P pregnant, STB syncytiotrophoblast, w weeks.
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Of the 319 secreted placental proteins in mouse and human, 56
were previously reported to be secreted from first trimester
human trophoblast organoids18, including progranulin (GRN),
IGF2, insulin-like growth factor-binding protein 2 (IBP2), and
macrophage migration inhibitory factor (MIF). Our analysis also
identified a small subset of proteins (24/319) that were previously
classified as DAMPs19. The fact that we and others also detected
at least 19 of these putative DAMPs in mouse plasma suggests
that even if these proteins are the outcome of cellular damage,
they could play a physiological role in either cell–cell commu-
nication or placental–maternal communication. We validated a
subset 45 proteins from our placental secretome map that were
detectable in mouse plasma of which more than 50% (24/45)
showed a higher relative abundance in pregnancy. Interestingly,
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several prolactins were also detectable in the plasma of pregnant
mice, which is remarkable given that 99.9% of proteins in the
circulation are comprised of ~20 high abundant plasma proteins,
severely limiting the ability to detect low abundant proteins.
However, given that the mass spectrometry analyses are not
capable of exhaustively detecting all proteins, we cannot exclude
lack of pregnancy-related changes for any of the other 319 pro-
teins in our placental secretome map in the circulation and hence
further verification is needed in the future. Indeed, the majority of
the proteins in our secretome map (300 out of 319) were localized
to the STB of the human placenta17, which is in direct contact
with maternal blood and the primary site for hormone produc-
tion in the human placenta. The predominate localization of
proteins in our secretome map to the STB in humans validates
our method and highlights how data generated may improve our
understanding of the role and regulation of human placental
endocrine function. More than 60% of the proteins in our pla-
cental secretome map were predicted to function in “response to
stimulus”. This GO term includes secondary biological groups
such as regulation of signal transduction downstream of the
interleukin-1 receptor type 2 (IL1R2), macrophage metalloelas-
tase (MMP12), and apolipoprotein A-I (APOA1) that participate
in the response to cytokines. It also included insulin-like growth
factor-binding proteins (IGFBP2, IGFBP4, and IGFBP6), which
modulate the mitogenic and metabolic actions of IGF that play
important roles in pregnancy physiology24. Indeed, several of
these proteins have been previously shown to be secreted from
the human placenta, such as the IL1R225, IGF2 and IGFBPs26,
MMP1227, and APOA128 and are consistent with our findings.
Many of the proteins in our secretome map were also identified to
be hormone-binding proteins, or proteins that regulate signaling
downstream of receptors. These included annexin A5 (ANXA5)
an anticoagulant protein, inhibin beta A chain, which is a subunit
of both inhibin and activin, transthyretin (TTHY) a thyroid
hormone-binding protein, insulin-degrading enzyme (IDE),
which binds to insulin and leukemia inhibitory factor receptor
(LIFR). Whilst proteins like ANXA5, inhibins/activins, TTHY,
and LIFR have been previously reported to be secreted from the
placenta1,29–31, we are not aware of any studies describing the
secretion of other proteins, like IDE from the human placenta.
Furthermore, other secreted proteins such as adipocyte enhancer-
binding protein 1 (AEBP1) and Y-box-binding protein 1
(YBOX1), which can regulate transcription were also detected in
the placental secretome. Again however, to date, there are no
studies related to the secretion of AEBP1 and YBOX1 from the
human placenta. Collectively our findings may suggest that the
secretome map comprises known and novel secreted placental
proteins.
Two main protein domains featured in our placental secretome
map were the “Serpin conserved site” and the “EGF-like domain”
which are important in regulating inflammatory processes,
growth factor signaling and extracellular matrix and cytoskeletal
remodeling. Thus, in addition to identifying proteins secreted by
the placenta with systemic actions, proteins in our secretome map
may also play local autocrine and paracrine roles in modulating
processes at the fetal–maternal interface, including decidual
remodeling/function, immune tolerance, and placentation. Using
tissue gene expression enrichment analysis, we found that of the
proteins in our placental secretome map, 20 were most abun-
dantly expressed by the placenta in mouse and 4 were enriched in
the placenta in human. Of note, TFPI2 a plasmin-mediated
matrix remodeling, FLT1 a receptor for vascular endothelial
growth factor and proteins from the SERPIN family were enri-
ched in both the mouse and human placenta. This is consistent
Fig. 4 Applying the secretome map of the placenta to data available for human pregnancy complications. a Venn diagram showing the number of
placental proteins in the secretome map that are differentially expressed in the placenta of women with a pregnancy complication (LGA: green, GDM:
orange, PE: blue, IUGR: gray, and SGA: red ovals. b FLT1 expression at the maternal–fetal interface of early human pregnancy via the CellxGene tool
(https://maternal-fetal-interface.cellgeni.sanger.ac.uk/). Highest score in blue and 0.0 score in light green. c Serum levels of FLT1, MIF, ANGP2, and IGF2
in pregnant women at 12 (blue box plot) and 28 weeks (purple box plot) of gestation who went on to have normoglycemic (healthy) pregnancies or
developed GDM. Data are expressed as multiple for the median, MoM. The box blot shows the minimum and maximum values as whiskers, the median
line as a solid line and the first (25th percentile) and third quartiles (75th percentile) represented by box length. Raw data for proteins levels are shown in
Supplementary Fig. 5. d Ratio of the levels of FLT1 to MIF and ANGPT2 to MIF at week 12 of pregnancy in healthy women (blue circles) and those who went
on to develop GDM (orange squares). Data are presented as mean ± SEM of MoM. Asterisks denote statistical significance to the GDM pregnancies, using
two-way ANOVA (c) and t-test (d), *p < 0.05, **p < 0.01, n= 10–11 for healthy pregnancies, n= 6 for GDM. GA gestational age, GDM gestational diabetes
mellitus, IUGR intrauterine growth restriction, LGA large for gestational age, PE preeclampsia, SGA small for gestational age.
Table 1 Clinical characteristics of women used for the analysis of circulating placental hormone abundance in human pregnancy.
Characteristics Healthy pregnancy (n= 10) GDM pregnancy (n= 6) p value
Parity 1.14 ± 0.26 1.29 ± 0.52 0.78
Early pregnancy BMI 33.45 ± 1.78 35.37 ± 2.42 0.52
GA at OGTT 28.513 ± 0.75 26.55 ± 1.83 0.28
OGTT 0 h (mmol/l) 4.46 ± 0.07 5.07 ± 0.2 0.002
OGTT 2 h (mmol/l) 5.65 ± 0.23 7.66 ± 0.94 0.014
Systolic BP (mm Hg) 1st trimester 116.8 ± 0.8 112.5 ± 1.8 0.386
Diastolic BP (mm Hg) 1st trimester 71.09 ± 0.84 68.0 ± 2.1 0.576
Systolic BP (mm Hg) 2nd trimester 117 ± 1.75 122.5 ± 4.26 0.541
Diastolic BP (mm Hg) 2nd trimester 70.66 ± 1.6 71.75 ± 3.43 0.855
HBA1C (mmol/mol) 33.42 ± 0.58 36.0 ± 0.53 0.01
GA at delivery 39.47 ± 0.41 38.76 ± 0.57 0.30
Birthweight (g) 3556.36 ± 126.24 3392.1 ± 170.00 0.44
Infant sex (F/M) 5/5 2/4
Data are shown as mean ± SEM and analyzed by t-test.
GA gestational age, BP blood pressure, F female, M male, OGTT oral glucose tolerance test.
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Fig. 5 Transcription factors dysregulated in pregnancy complications identified as possible regulators of genes encoding secreted placental proteins. a
Table showing the ten transcription factors with altered expression in pregnancy complications and with binding sites enriched at the promoters of genes
encoding proteins in the placental secretome map. b Regulatory network built with the ten transcription factors listed in a. The ten transcription factors and
their targets that are differentially expressed in pregnancy complications are highlighted in purple. Location of the target proteins is according to their main
cellular/extracellular compartment indicated by IPA. The graph was generated using BioRender.
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with the findings of others showing genes and proteins in the
placenta overlap in the two species14,15. Indeed, as a key aim of
our work was to create a secretome map that would be applicable
for both human and mouse, we used orthologue searches in our
initial steps in narrowing our list of protein candidates. We found
that the majority of the proteins we found in our mouse placental
endocrine cell protein lists were also expressed by the human
placenta, which is higher than reported previously for other
placental datasets. However, of note, we found that there were an
additional 31 secreted proteins in our complete placental secre-
tome map, which were only expressed by the mouse and not
the human placenta. These included 17 members of the PRL/PL
gene family and 7 members of the cathepsin gene family, which
have both undergone robust species-specific expansion, particu-
larly in rodents, and exhibit unique spatial expression patterns by
endocrine trophoblast lineages in mice32,33. Overall, PRL/PL and
cathepsin family members are thought to play divergent roles in
driving physiological changes in the mother during pregnancy,
including modulation of insulin production and action, vascular
remodeling and immune system regulation. However, further
work is required to understand the significance of individual
family members to determining pregnancy outcome.
Using a collection of published datasets, we identified that
around 30–40% of proteins in our placental secretome map (319
proteins expressed by human and mouse placenta) were reported
to be aberrantly expressed by the human placenta in pregnancy
complications. Moreover, we found four secreted placental pro-
teins to be differentially expressed in the placenta of women who
developed PE, GDM, IUGR, and SGA. This suggests that there
may be common pathways related to the production of specific
placental hormones, which may underlie or be reflective of the
development of such pregnancy complications. Alternatively,
the common expression of secreted placental proteins between
these four pregnancy complications may reflect that there is
overlap between these pregnancy complications, as PE often leads
to IUGR or SGA and GDM is linked to PE. Interestingly, two of
these proteins; FLT1 and IGF2 were highly enriched in the
human placenta compared to other tissues. Moreover, circulating
FLT1 (sFLT1) has been previously reported as a suitable bio-
marker for PE, IUGR, and SGA. Whilst the expression of the
FLT1 gene is reported to be altered in the placenta of women with
GDM, previous work has not evaluated whether sFLT1 levels are
altered and could serve as a biomarker for GDM pregnancies.
Similarly, IGF2 was also reported to be altered in the placenta in
PE, IUGR, GDM, and SGA pregnancies, however, less is known
about changes in circulating IGF2 in the mother34–39. Aside from
being altered in LGA pregnancies, ANGPT2 and TIMP3 in our
secretome map were also reported to be differentially expressed
by the placenta in the pregnancy complications assessed.
ANGPT2 has previously been explored as predictive candidate
biomarker for PE, however it was shown to be unsuccessful40. In
the context of GDM, ANGPT2 has been reported be differentially
secreted from cultured trophoblast of the term placenta in GDM
pregnancy41, but no maternal serum analysis was described.
Similarly, altered placental expression of ANGPT2 was reported
for SGA42 and one study has found it to serve as a predictive
biomarker for IUGR43.
We identified several secreted placental proteins altered spe-
cifically in some of the pregnancy complications we studied.
Analyzing the GO terms of these unique groups of proteins
revealed that for those uniquely altered in PE, they were impli-
cated in the control of immune processes, platelet aggregation,
and leukocytes like neutrophils, which is in line with previous
work focussed on understanding the pathogenesis of PE in
women44. Similarly, GO analysis of the secreted placental pro-
teins specifically altered in GDM featured terms including protein
metabolism, extracellular matrix remodeling, and the control of
the unfolded protein response and is consistent with studies
exploring the etiology of GDM45. Secreted placental proteins
changed in IUGR are proposed to be involved in fibril, collagen,
and laminin interactions, however the functional relevance of this
finding requires further study.
As a proof of concept that our methodology and placental
secretome map may be beneficial for illuminating potential cir-
culating biomarkers with clinical relevance, four secreted pla-
cental proteins (sFLT1, MIF, ANGPT2, and IGF2) were assessed
in the serum of women who had normal or GDM pregnancies.
All four proteins were detectable as early as 12 weeks of gestation.
We found that across the two gestational time points, sFLT1 was
overall higher in the circulation of women who developed GDM.
This was despite the fact that the women with GDM were nor-
motensive. Studies previously exploring changes in sFLT1 in
GDM pregnancies have yielded inconsistent results. There was no
difference in circulating sFLT1 concentration in lean women with
and without GDM in the third trimester of pregnancy46, and no
difference in the secretion of sFLT1 by term placental explant
from women who developed GDM47. However, sFLT1 has been
reported to be elevated in the early second trimester (16–20 weeks
of gestation) in women who went on to develop GDM in later
pregnancy48, which is in line with our findings. The relationship
between placental sFLT1 production and the development of
GDM warrants further study.
We found that the circulating levels of ANGPT2 and IGF2
were not different between women with normal glucose tolerance
or GDM at either 12 or 28 weeks of gestation. However, circu-
lating levels of MIF in the mother failed to decline in women with
GDM between these two gestational time points. Moreover, the
ratios/relationships between the concentrations of MIF to sFLT1
and ANGPT2 to MIF were altered in women at week 12 of
pregnancy, which is at least 10 weeks before diagnosis of GDM,
suggesting that they may serve as potential early biomarkers for
GDM. MIF promotes the secretion of insulin from beta cells and
also increases glucose uptake by skeletal muscle49, thus its sig-
nificance in development of GDM should be explored further.
The value of assessing the ratio/relationship between the con-
centration of different biomarkers in the maternal circulation for
early detection of pregnancy complications is supported by pre-
vious work showing a change in the ratio of sFLT1 to PIGF for
PE, as well as IUGR in women2,50. However, it is important to
note that while many previous studies assessing pregnancy bio-
markers have used multiple of the median (MoM)51–53 as we
have done so here, the absolute values for the proteins quantified
were not statistically significant. In addition, the significance
observed with the ratio of MoM values may be due to the cal-
culation placing greater weighting on the MIF results. Finally, the
number of women with normal glucose tolerance and GDM in
our study was small, and both groups had an elevated body mass
index. Further work is required to validate our findings of a
change in the ratios/relationships between MIF to sFLT1 and
ANGPT2 concentrations in larger cohorts and in women who
have a normal body mass index.
It remains to be determined whether more promising data may
be obtained from a secretome map of the mouse placenta at an
earlier time point in pregnancy, which is more equivalent to the
time points examined in our human validation study (day 16 of
mouse pregnancy may be considered the start of the last trimester
of human pregnancy, which is much later than weeks 12 and 28
of human gestation when screening tests take place). Moreover,
work is required to further explore the clinical value of generating
a secretome map of the placenta utilizing our approach and if
data on multiple secreted proteins or a network of proteins would
improve the accuracy of diagnosis of complications like GDM.
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Finally, it should be acknowledged that while most hospital
laboratories do not have access to sophisticated proteomic ana-
lysis, many proteins identified by the current study can be mea-
sured in other ways, for example, using immunoassays, which
could be automated, facilitating widespread availability. Techni-
ques such as multiplexing also make it feasible to run multiple
related assays simultaneously. Indeed, the antenatal screening
program (first or second trimester) is a good example of the
ability of multiple measured biomarkers to identify high-risk
pregnancies, with improved performance using a panel of bio-
markers over a single test. While this may not be immediately
accessible to hospital laboratories in lower-resource settings,
many countries run an antenatal screening program already, and
integration of new test panels into that existing infrastructure is
feasible. The aim of this study was not to provide new clinically
validated biomarker panels ready for diagnostic/predictive use,
but rather to provide a resource to support future development of
biomarkers or biomarker panels, which may be very valuable in
multiple disease areas.
We identified 33 TFs that are expressed by the STB of the
human placenta and are predicted to control the gene expression
of ~30% of the proteins in our placental secretome map (and are
also expressed by the STB at the same time). Of these, ten were
previously linked with pregnancy complications. These included
ARNT2, which is dysregulated in the placenta of women with PE
and IUGR and modulates the expression of genes that are also
reported to be altered in human pregnancy complications, such as
ANGPT212. ARNT2 is implicated in mediating cellular responses
to stimuli including hypoxia54 and our findings are consistent
with recent work applying an integrated systems biology
approach55. We also identified TFs, PLAG1, and CREB1 that
were altered in the placenta of GDM pregnancies and were pre-
dicted to modulate the expression of numerous proteins in our
secretome map including those that were additionally differen-
tially expressed in GDM, such as IGF2 and FLT1. Consistent with
this, CREB1 is regulated by metabolic stimuli like glucose56 and
PLAG1 was pinpointed as a critical factor altered in women who
developed a complicated pregnancy57. In addition, both PLAG1
and CREB1 have been reported to be dysregulated in mouse
genetic models showing placental dysfunction and/or poor
pregnancy outcome58,59. Thus, numerous TFs likely govern the
endocrine function of the placenta and may have significance for
understanding the pathogenesis of human pregnancy complica-
tions. Hence, future work should center on testing the sig-
nificance and upstream regulators of TFs identified as putative
regulators of placental hormone production.
Many of the biomarkers or functional and transcriptional
pathways identified using our approach have been previously
suggested or shown to be associated with adverse pregnancy
outcomes. This validates our methodological approach, as well as
the findings of others that such markers/pathways may indeed be
involved in the pathogenesis or serve as diagnostic indicators of
those pregnancy complications, thereby reinforcing further work
on them. However, it is important to note that several previously
unrecognized or understudied markers and pathways were
also identified using our approach (e.g., IDE and TTHY as
unrecognized placental hormones potentially involved in
placental–maternal communication, and unfolded protein
response for GDM and neutrophil degranulation for PE), which
provides further added value and could be tested more specifically
in future work.
In summary, we have generated a comprehensive secretome
map of the placenta. This map was proven to be suitable for
gaining further information on the significance and regulation of
placental endocrine function in mice and humans. Furthermore,
we have uncovered different types of secreted placental proteins,
which function in the endocrine and paracrine regulation of
maternal physiology, but also possibly in an autocrine manner to
modulate placental biology. Sex differences in placental function
and pregnancy outcomes are of increasing clinical relevance. As
our placental secretome map represents data from both fetal sexes
(mouse placentas were obtained from females and males for cell
culture and sorting experiments, published datasets used in ver-
ification steps did not consider fetal sex, and due to small sample
size our human validation study was not split by sex), future work
should investigate the extent to which fetal sex modifies the
placental secretome and its implication for maternal physiological
adaptations during pregnancy. Whether secreted placental pro-
teins may reach the fetal circulation to modulate fetal growth also
requires further exploration. However, our placental secretome
map revealed that more than 100 proteins may be differentially
secreted from the placenta in complicated human pregnancies.
Further work is required to extend our findings, including by
employing the same methodology and bioinformatics pipeline
however, using placental endocrine cells taken from other
gestational ages and pregnant mice exposed to environmental
conditions, such as maternal obesity, which is a risk factor for
complications like PE, GDM, and abnormal birthweight. This will
further build knowledge on the role and control of the endocrine
placenta during pregnancy and may pave the way for the dis-
covery of novel or improved biomarkers for early detection and
prevention of pregnancy complications.
Methods
Mouse studies. Mouse studies were approved by the University of Cambridge
Ethical Review Panel and performed in accordance with the UK Home Office
regulations Animals (Scientific Procedures) Act 1986 (project licence 70-7645 and
PC6CEFE59). All mice used (wild type and transgenic) were on a C57BL/6J genetic
background and housed under 12 h dark–light conditions with free access to water
and the standard diet (RM3, special dietary services) used in the University of
Cambridge Animal Facility. For the preparation of primary cultures of junctional
zone trophoblast endocrine cells, wild-type females were mated with males
homozygous for Tpbpa-Cre-EGFP transgene13. For the FACS of junctional zone
trophoblast endocrine cells, Tpbpa-Cre-EGFP homozygote males were mated to
females homozygous for the double-fluorescent Cre reporter construct, mTmG,
which expresses membrane-targeted tdTomato prior to, and membrane-targeted
EGFP following, Cre-mediated excision (kind gift from Dr. Marika Charalambous,
King’s College London16). The day a copulatory plug was found was denoted as day
1 of pregnancy (term is 20.5 days). Placentas were harvested from mouse dams that
were schedule 1 killed by cervical dislocation on day 16 of pregnancy. Female mice
were 8–14 weeks when mated and stud male mice were more than 16 weeks of age
when used for time-matings.
In a separate set of experiments, age-matched virgin and pregnant (day 16)
wild-type C57BL/6J females were anaesthetized with an intraperitoneal injection of
fentanyl (sublimaze or fentadon): midazolam (hypnovel): ketamine (ketavet/
narketan/ketaset) in sterile water for injection (1:1:0.16:1.63) at 0.15 ml/10 g. After
confirming anesthesia, the chest cavity was exposed, and blood was collected by
cardiac rupture prior to confirming the animal was schedule 1 killed by cervical
dislocation. Blood was collected into an EDTA tube, shaken and placed on ice until
it was centrifuged at 3000 rpm for 10 min and plasma recovered and stored at
−20 °C until analysis.
Preparation of primary cultures of junctional zone trophoblast endocrine cells.
Placentas (average of 6–8 per mouse dam) were enzymatically dissociated using a
buffer (Medium 199 with Hank’s salts, 20 mM HEPES, 10 mM NaHCO, 50 U
penicillin/ml, and 50 pg streptomycin/ml, pH 7.4) containing 0.1% collagenase and
0.002% DNase at 37 °C for 1 h, as described previously23. Dissociated samples were
passed through a 200 µM nylon filter to remove tissue debris and cells were cen-
trifuged at 500 × g for 5 min. Cell pellets were resuspended with Medium 199 ×1
and cells subsequently separated using a three-layer Percoll density gradient (1.028,
1.05, and 1.088 g/ml) according to manufacturer instructions (Percoll plus, GE
Healthcare Life Sciences) and as described previously by centrifuging at 600 × g for
30 min with controlled acceleration and braking. Layers from the density gradient
were recovered into Medium 199 X1 to dissolve the Percoll solution. Cells were
then centrifuged for 5 min at 500 × g and further washed with PBSX1 prior to
counting using Haemocytometer. Cells isolated from each layer of the Percoll
gradient were fixed with 4% PFA for 20 min and subjected to 5 µ/ml of Hoechst
solution for 10 min at 37 °C. Cells were then visualized using fluorescence
microscopy (Leica TCS SP8 Confocal laser scanning microscope) and the second
layer was found to contain the greatest density of junctional zone trophoblast
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endocrine cells (EGFP-positive cells due to Tpbpa-Cre-EGFP) and therefore used
for further analysis. Namely, cells in the second Percoll density layer were seeded in
96-well plates, 8 chamber slides or in 6-well plates (105 cells/ml) and time of
seeding was defined as time 0. Cells were grown in NTCT-135 medium containing
10% fetal bovine serum, 50 IU/ml ampicillin, 50 µg/ml streptomycin, 2 mM l-glu-
tamine, 20 mM HEPES, and 10 mM NaHCO and maintained in a humidified
atmosphere of 5% CO2 at 37 °C. Cell medium was replaced every 24 h. Cells were
washed three times in PBSX1 and serum-free medium applied 24 h prior to any
downstream analysis.
Viability assay. Cell viability was determined using an XTT cell proliferation assay
kit (Abcam—ab232856) according to manufacturer’s instructions. Values were
calculated as % of values at time 0 h and each experiment was performed in
triplicate in 8–10 independent assays.
Cell death assay (LDH release assay). Cell death was determined by measuring
the activity of lactate dehydrogenase (LDH) in the conditioned media of primary
cell cultures using a LDH cytotoxicity assay kit, according to the manufacturer’s
instructions (Thermo Scientific). Cell-free medium and cells treated with medium
containing Triton-X were used as negative and positive controls, respectively. Each
experiment was performed in triplicate in six independent assays.
In situ hybridization. In situ hybridization was performed on primary cell cultures
seeded on chamber slides at 90% confluency (106 cells/well) (Thermo Fisher Sci-
entific, UK). Cells were fixed in 4% PFA for 30 min, washed twice with PBSX1,
dehydrated in increasing concentrations of ethanol and stored in 100% ethanol at
−20 °C. In situ hybridization was performed using the RNAScope 2.5 RED
chromogenic assay kit following the manufacturer’s instructions (Bio-Techne, UK).
Briefly, slides were allowed to equilibrate to room temperature and rehydrated in
PBSX1. RNAscope® Hydrogen Peroxide was applied to the slides for 10 min at RT,
followed by RNAscope® Protease Plus in RT for 10 min. Slides were then incubated
with the target or control probes at 40 °C for 2 h (negative control probe (310043),
positive control probe (313911), Tpbpa-probe (405511), Prl8a8-probe (528641),
Gjb3-probe (508841), and Hand1-probe (429651) in a HybEZ oven for 2 h at 40 °C.
Next, slides were washed twice with wash buffer and were subjected to six rounds
of amplification and the probe signal was developed via a reaction with fast red.
Slides were then counterstained with Haematoxylin and mounted in EcoMount.
Slides were scanned on a NanoZoomer 2.0-RS slide scanner (Hamamatsu,
Hamamatsu City, JP) at ×40 magnification.
Conditioned medium preparation for mass spectrometry. Conditioned medium
from cultured cells was collected at 48 h of culture. At 24 h prior to medium
collection, cells were washed three times with PSBX1 and cultured in serum-free
medium. The conditioned medium was centrifuged at 1000 × g for 10 min and total
protein concentration measured using a Bradford assay. Proteins in the condi-
tioned medium were concentrated up to 1.2 μg/μl of total protein using cellulose
membrane Ultra-4 Centrifugal Filter Unit of 3 KDa cut-off (Merck) as per the
manufacturer instructions.
RNA extraction and quantitative real-time PCR (qPCR). Total RNA was
extracted from cultured cells using RNeasy Plus Mini Kit (QIAGEN) and 0.5 µg of
RNA was reverse transcribed with random hexamer primers using a High-Capacity
cDNA RT kit (Applied Biosystems) according to the manufacturer’s instructions.
qPCR was performed using MESA BLUE qPCR Master Mix (Eurogentec) on a Bio-
Rad T100 thermocycler using gene-specific intron-flanking primers. In particular,
forward and reverse primers for Tpbpa are: TGAAGAGCTGAACCACTGGA and
CTTGCAGTTCAGCATCCAAC, Mct4: GGCTGGCGGTAACAGAGTA and
CGGCCTCGGACCTGAGTATT, Prl8a8: TCAGAGCTGCATCTCACTGC and
GGGACATCTTTCATGGCACT, Gjb3: GGGGCTCTCCTCAGACATA and
ACCTGCTAGCCACACTTGCT, Hand1: GGAGACGCACAGAGAGCATT and
CACGTCCATCAAGTAGGCGA, and Krt18: CAAGACCTGAACCGTCGCCT
and ATTCGCAAAGATCTGAGCCCT, respectively. Gene expression was ana-
lyzed in triplicate and the Ct values were normalized to the expression of internal
housekeeping genes (Gapdh, RpII, and Hprt). Forward and reverse primers for
Gapdh are: GGGAAATGAGAGAGGCCCAG and GAACAGGGAGGAGCAGAG
AG, RpII: AGATGTATGACGCCGACGAG and AATCGGTGGTGCATCTTCCA,
and Hprt: CAGGCCAGACTTTGTTGGAT and TTGCGCTCATCTTAGGCTTT,
respectively. Results are presented as mean ± SEM and relative to time 0 h.
Fluorescence-activated cell sorting (FACS) of live cells for mass spectro-
metry. Single-cell suspensions were prepared from whole placentas digested with
the dissociation buffer containing 0.1% collagenase and 0.002% DNase at 37 °C for
1 h, as described for the preparation of primary cell cultures. Cells were filtered
through 100 µM nylon filter and centrifuged at 500 × g for 5 min. Cell pellets were
resuspended with PBSX1 and 7AAD (Life Technologies, A1310) added prior
sorting using a FACSJazz machine (BD Biosciences, Singapore). Live cells were
gated and cells positive for EGFP or tdTomato were sorted and lysed directly into
80% acetonitrile (ACN) in water (v/v) in a Protein LoBind Eppendorf tube.
Mass spectrometry
LC-MS/MS analysis of conditioned media. Conditioned media from primary cul-
tures of trophoblast cells were standardized to a final concentration of 2 µg/µl in 4%
SDS loading buffer with 100 mM dithiothreitol (DTT). Samples were denatured at
95 °C for 5 min and 10 µg of total protein per sample was loaded onto a 12% SDS
PAGE gel and run at 120 Volts. The gel was then stained with colloidal coomassie
stain and washed with water. Protein bands in each lane were cut into 1 mm2
pieces, de-stained, reduced (using DTT), and alkylated (using iodoacetamide) and
subjected to enzymatic digestion with sequencing grade Trypsin (Promega,
Madison, WI, USA) overnight at 37 °C. After digestion, the supernatant was
pipetted into a sample vial and loaded onto an autosampler for automated LC-MS/
MS analysis. All LC-MS/MS experiments were performed using a Dionex Ultimate
3000 RSLC nanoUPLC (Thermo Fisher Scientific Inc, Waltham, MA, USA) system
and a Q Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific Inc,
Waltham, MA, USA) as described previously60.
For medium generated spectra, all MS/MS data were converted to mgf files and
the files were then submitted to the Mascot search algorithm (Matrix Science,
London UK, version 2.6.0) and searched against the UniProt mouse database
(61,295 sequences: 27,622,875 residues) and a common contaminant sequences
containing non-specific proteins such as keratins and trypsin (115 sequences,
38,274 residues). Variable modifications of oxidation (M) and deamidation (NQ)
were applied, as well as a fixed modification of carbamidomethyl (C). The peptide
and fragment mass tolerances were set to 20 ppm and 0.1 Da, respectively. A
significance threshold value of p < 0.05 and a peptide cut-off score of 20 were also
applied. All data (DAT files) were then imported into the Scaffold program
(Version 4.5.4, Proteome Software Inc, Portland, OR). LC-MS/MS experiments
were partially performed at Cambridge Centre for Proteomics.
LC-MS/MS analysis of primary cultured cells and sorted cells. Trophoblast from
both primary cell cultures and fluorescence activating cell sorting were treated with
800 µl of 80% ACN in water and centrifuged for 5 min at 10,000 × g. The super-
natant was removed and the pellet was reduced and alkylated using 50 mM
ammonium bicarbonate and 10 mM DTT at 60 °C for 1 h, followed by the addition
of 100 mM iodoacetamide in the dark for 30 min. Enzymatic digestion was per-
formed using Trypsin at 10 µg/ml in 50 mM ammonium bicarbonate overnight at
37 °C (enzymatic digestion was halted by the addition of 1% formic acid). Samples
were analyzed by LC-MS using a Thermo Fisher Ultimate 3000 nano LC system
coupled to a Q Exactive Plus Orbitrap mass spectrometer (Thermo Scientific, San
Jose, CA, USA), as described previously61. For generated spectra, all LC-MS files
were searched using PEAKS 8.5 (Bioinformatics Solutions Inc) software against the
Swissprot database (downloaded 26-Oct-2017) with a Mus musculus filter. A
tryptic digestion approach was selected using a semi-specific setting and up to a
maximum of three missed cleavages. The search outputs had a 1% FDR setting
applied, along with a unique peptide setting of at least one peptide. The precursor
and product ion tolerances were 10 ppm and 0.05 Da, respectively.
LC-MS/MS analysis of mouse plasma. Plasma was defrosted and an equal volume of
6 M guanidine hydrochloride was added and the sample mixed thoroughly. Pro-
teins were precipitated by the addition of 75% ACN in water at a ratio of 1:6
(diluted plasma:ACN), and the sample centrifuged at 2900 × g for 10 min at 4 °C.
The supernatant was transferred and evaporated under oxygen free nitrogen. The
extract was reconstituted into 200 µl of 0.1% formic acid in water and extracted
using solid phase extraction. The eluent was evaporated and reduced and alkylated
prior to overnight trypsin digestion. Extracts were acidified and analyzed using
nano LC-MS and the data searched using PEAKS as described above. Peptides
from specific proteins of interest in the PEAKS search result were selected for
targeted quantitation in the raw LC-MS files. The most abundant peptide from
each protein was selected and their m/z values were used to generate extracted ion
chromatograms using the Xcalibur LCQuan program (Thermo Fisher Scientific)
and the peak areas of each peptide was expressed as a ratio of a digested peptide
from the spiked internal standard peptide (bovine insulin)61,62.
Bioinformatics analysis. Protein/peptide annotations in LC-MS datasets were
converted to their gene accession ID via UniProt (https://www.uniprot.org/
uploadlists/). Gene lists were then overlaid with publicly available datasets for the
mouse and human placenta, which are detailed in Supplementary Table 1 (three
from mouse placenta and eight for human placenta). Mouse–human ortholog
searches were also undertaken using three sources of data, MGI (http://www.
informatics.jax.org/), NCBI (https://www.ncbi.nlm.nih.gov/homologene), and
Ensembl (biomaRt_2.42.1 and homologene_1.4.68 in R version 3.6.2; https://www.
R-project.org/). Then using R, a combined ortholog list for Mouse–Human was
generated (details of the list and Rscript can be found in GitHub, https://github.
com/CTR-BFX/2020-Napso_Sferruzzi-Perri). Mouse–human ortholog results were
classified as one-to-one when a gene/protein from mouse was found at the end of a
node in human. Any results classified as one-to-many were excluded. GO analyses
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were performed using both STRING and Panther tools (https://string-db.org/).
Gene enrichment analyses were conducted using TissueEnrich (https://
tissueenrich.gdcb.iastate.edu/), which utilizes datasets available in the Human
Protein Atlas compiling RNA-seq datasets from 35 human tissues and the Mouse
ENCODE database comprised of RNA-seq datasets of 17 mouse tissues. Heat map
of MS peak areas of each peptide (normalized to the internal standard—bovine
insulin) detected in mouse plasma was generated using Heatmapper (http://www.
heatmapper.ca/expression/) using Average Linkage as clustering method and
Spearman Rank Correlation as distance measurement method, applied to both
columns and rows. Refined gene/protein lists were overlaid with publicly available
RNA and protein expression datasets for human pregnancy complications (Sup-
plementary Table 3) and aided by searches in Pubmed and the OMIM repository
(http://www.ncbi.nlm.nih.gov).
To further refine our lists to secreted proteins, we applied SignalP (Signal
Peptide Prediction, version 4.163) and GO analysis using four different GO terms:
extracellular region (GO: 0005615), extracellular exosome (GO: 0070062),
extracellular region parts (GO: 0005615) and signal IP (excluding signals detected
for ER lumen proteins)64. This was undertaken because SignalP can only detect the
signal peptide for proteins secreted via the canonical route, which is also known as
the “classic” or “conventional” secretion pathway. However, eukaryotic cells also
utilize an unconventional protein secretion route for protein sorting and delivery,
an “unconventional” secretion pathway, including leaderless proteins that are
secreted into the extracellular space. This approach allowed us to capture proteins
that employ the “conventional”, as well as “unconventional” secretion pathways.
All data outputs at each step of the pipeline, including the proteins/genes expressed
in the mouse but not the human placenta and the refinement of our list to secreted
proteins can be found in GitHub (https://github.com/CTR-BFX/2020-
Napso_Sferruzzi-Perri). The mass spectrometry proteomics data have also been
deposited to the ProteomeXchange Consortium via the PRIDE partner repository
with the dataset identifier PXD025006.
To search for enrichment of TF binding motifs at the promoters of the genes
encoding the 319 proteins that are part of placental secretome, we first used
Eukaryotic Promoter Database (https://epd.vital-it.ch/index.php) to retrieve the
DNA sequences from 1000 bp upstream to 100 bp downstream of the
transcriptional start site. These sequences were then analyzed using Analysis of
Motif Enrichment v4.12.0 (http://meme-suite.org/tools/ame) by selecting Mus
musculus and HOCOMOCO Mouse (v11 FULL) as motif database. An additional
search for upstream regulators was performed using the IPA (Qiagen), and only
TFs predicted by both tools (n= 77) were selected for further analysis. Next, we
filtered for TFs with enriched expression in STB cells from human placenta at
8 weeks of gestation that had at least one common target gene encoding one of the
319 placental secretome proteins (n= 33). Literature search led to identification of
ten of those TFs that were linked with pregnancy complications. Transcriptional
network visualization for the ten TFs and the corresponding targets was performed
using IPA.
Human study population and sampling. The recruitment of human subjects was
performed in accordance with relevant guidelines and regulations and approved by
the Research Ethics Committee under agreement REC 18/LO/0477 as part of the
Observational study of pregnancy hyperglycemia, endocrine causes, lipids, insulin
and autoimmunity study (OPHELIA; approved 5 April 2018; Research Registry
number 552865; described in detail elsewhere66). All participants provided written
informed consent prior to participation. Inclusion criteria included (1) singleton
pregnancy, (2) no evidence of severe congenital anomaly, and (3) a referral for an
OGTT for clinical reasons, according to NICE guidelines (https://www.nice.org.uk/
guidance/ng3). Exclusion criteria for this study were (1) multiple pregnancy, (2)
severe congenital anomaly on ultrasound, (3) severe anemia on previous blood
tests, (4) previous diagnosis of diabetes outside of pregnancy, and (5) medications
at the time of the OGTT, which may interfere with the results of the OGTT.
Screening for GDM was performed at 24–28 weeks of gestation using a 75 g OGTT
and diagnosis of GDM was made in accordance with the IADPSG glycaemic cut-
off values (fasting value ≥92 mg/dl (5.1 mmol/l), 1 h post-glucose load ≥180 mg/dl
(10 mmol/l), 2 h post-glucose load ≥153 mg/dl (8.5 mmol/l). Venous blood samples
were collected from pregnant women in the first trimester (12 weeks of gestation)
and second trimester (28 weeks of gestation) at the same time as routine clinical
venesection. Plasma was recovered by 2500 rpm for 10 min and samples were
stored at −80° C. Blood pressure measurements were taken at various times in
pregnancy using a calibrated automatic oscillometric sphygmomanometer (Dina-
map machine) and systolic and diastolic blood pressure recorded. For inclusion in
this study, a cohort of patients were chosen retrospectively from the OPHELIA
pilot study including six women with GDM and a control group of age- and BMI-
matched participants with normal glucose tolerance (n= 10).
Human plasma analysis of protein candidates by ELISA. Candidate secreted pla-
cental proteins were quantified in maternal plasma samples from healthy women
and those diagnosed with GDM, using commercially available ELISAs for sFLT1
(K15190D, MSD), MIF (K151XJK-1, MSD), ANGPT2 (F21YR-3, MSD), and IGF2
(DG200, R&D) by the Core Biochemical Assay Laboratory, Cambridge and
according to the manufacturer’s instructions.
Statistics and reproducibility. Data for viability, cell death, and qRT-PCR are
presented as mean ± SEM. Data were considered normally distributed
(Shapiro–Wilk normality test) and analyzed by two-way ANOVAs (with Tukey
correction for multiple comparisons) or t-tests to determine significant differences.
The number (n) of samples per group for each analysis and specific statistical test
employed are detailed in each figure legend for every dataset. All analyses were
performed using GraphPad Prism version 7.00 (GraphPad Software). Any
adjustment of p values based on Bonferroni correction are stated in the corre-
sponding figure legend. p < 0.05 was considered to indicate a statistically significant
difference between the groups analyzed.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All source data underlying the graphs and tables are available in Supplementary Data files
and/or can be found in GitHub (https://github.com/CTR-BFX/2020-Napso_Sferruzzi-
Perri) with corresponding DOI 10.5281/zenodo.464265367. The mass spectrometry
proteomics data have also been deposited to the ProteomeXchange Consortium via the
PRIDE partner repository with the dataset identifier PXD025006. All other data (if any)
are available upon reasonable request.
Code availability
The in-house scripts used for the analysis can be found in the following online repository:
https://github.com/CTR-BFX/2020-Napso_Sferruzzi-Perri67. The bioinformatics
software used are R version 3.6.2 (corresponding package versions are listed in GitHub),
SignalP version 4.1, GraphPad Prism version 7.00, and AME version 4.12.0.
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